Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials

Figure 5

ORR between gefitinib and no gefitinib group in different patients. (a) ORR between gefitinib and no gefitinib group in patients with advanced head and neck cancer (RR: 1.04; Z=0.52; P = 0.60). (b) ORR between gefitinib and no gefitinib group in patients with recurrent head and neck cancer (RR: 1.29; Z=0.66; P = 0.51).

(a)

(b)